JN Atkins

637 total citations
22 papers, 500 citations indexed

About

JN Atkins is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, JN Atkins has authored 22 papers receiving a total of 500 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Pulmonary and Respiratory Medicine, 14 papers in Oncology and 8 papers in Cancer Research. Recurrent topics in JN Atkins's work include Cancer Treatment and Pharmacology (7 papers), Lung Cancer Treatments and Mutations (7 papers) and Breast Cancer Treatment Studies (6 papers). JN Atkins is often cited by papers focused on Cancer Treatment and Pharmacology (7 papers), Lung Cancer Treatments and Mutations (7 papers) and Breast Cancer Treatment Studies (6 papers). JN Atkins collaborates with scholars based in United States, Italy and Canada. JN Atkins's co-authors include Norman Wolmark, M J O'Connell, Séamus O’Reilly, Greg Yothers, Saima Sharif, C. Klabunde, Carmen J. Allegra, Ramaswamy Govindan, Mark A. Socinski and Silvia Novello and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and International Journal of Radiation Oncology*Biology*Physics.

In The Last Decade

JN Atkins

21 papers receiving 482 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
JN Atkins United States	11	303	200	143	117	81	22	500
Molly Gabel United States	11	265 0.9×	97 0.5×	143 1.0×	45 0.4×	68 0.8×	17	480
Friedrich Overkamp Germany	13	356 1.2×	204 1.0×	206 1.4×	149 1.3×	28 0.3×	64	592
Katherine Enright Canada	10	412 1.4×	138 0.7×	216 1.5×	119 1.0×	64 0.8×	36	627
Farzana A. Faisal United States	15	269 0.9×	469 2.3×	157 1.1×	95 0.8×	73 0.9×	29	701
Tallal Younis Canada	15	331 1.1×	118 0.6×	165 1.2×	106 0.9×	80 1.0×	34	577
Sandra M. E. Geurts Netherlands	14	293 1.0×	176 0.9×	169 1.2×	95 0.8×	22 0.3×	59	612
M. Sassi Italy	7	361 1.2×	345 1.7×	78 0.5×	65 0.6×	37 0.5×	9	529
Lee Schwartzberg United States	8	333 1.1×	133 0.7×	92 0.6×	113 1.0×	25 0.3×	17	603
Alice Zervoudakis United States	11	690 2.3×	133 0.7×	320 2.2×	118 1.0×	61 0.8×	34	851
Bassim Al Bahrani Oman	12	207 0.7×	90 0.5×	81 0.6×	113 1.0×	49 0.6×	53	433

Countries citing papers authored by JN Atkins

Since Specialization

Citations

This map shows the geographic impact of JN Atkins's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by JN Atkins with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites JN Atkins more than expected).

Fields of papers citing papers by JN Atkins

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by JN Atkins. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by JN Atkins. The network helps show where JN Atkins may publish in the future.

Co-authorship network of co-authors of JN Atkins

This figure shows the co-authorship network connecting the top 25 collaborators of JN Atkins. A scholar is included among the top collaborators of JN Atkins based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with JN Atkins. JN Atkins is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

1.

Fehrenbacher, L., CE Geyer, Priya Rastogi, et al.. (2018). Abstract GS1-02: NSABP B-47 (NRG oncology): Phase III randomized trial comparing adjuvant chemotherapy with adriamycin (A) and cyclophosphamide (C) → weekly paclitaxel (WP), or docetaxel (T) and C with or without a year of trastuzumab (H) in women with node-positive or high-risk node-negative invasive breast cancer (IBC) expressing HER2 staining intensity of IHC 1+ or 2+ with negative FISH (HER2-Low IBC). Cancer Research. 78(4_Supplement). GS1–2. 40 indexed citations

2.

Gore, Elizabeth, Chen Hu, A. Sun, et al.. (2015). NRG Oncology/RTOG 0937: Randomized Phase 2 Study Comparing Prophylactic Cranial Irradiation (PCI) Alone to PCI and Consolidative Extracranial Irradiation for Extensive Disease Small Cell Lung Cancer (ED-SCLC). International Journal of Radiation Oncology*Biology*Physics. 94(1). 5–5. 10 indexed citations

3.

Julian, TB, D.W. Arthur, Ping Zheng, et al.. (2011). OT1-02-05: A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy to Radiation Therapy (RT) Alone for Women with HER2−Positive DCIS Resected by Lumpectomy: NSABP B-43.. Cancer Research. 71(24_Supplement). OT1–2. 3 indexed citations

4.

Shulman, L., C. Cirrincione, DA Berry, et al.. (2010). Abstract S6-3: Four vs 6 Cycles of Doxorubicin and Cyclophosphamide (AC) or Paclitaxel (T) as Adjuvant Therapy for Breast Cancer in Women with 0-3 Positive Axillary Nodes: CALGB 40101 — A 2x2 Factorial Phase III Trial: First Results Comparing 4 vs 6 Cycles of Therapy. Cancer Research. 70(24_Supplement). S6–3. 4 indexed citations

5.

Wolmark, Norman, Greg Yothers, M J O'Connell, et al.. (2009). A phase III trial comparing mFOLFOX6 to mFOLFOX6 plus bevacizumab in stage II or III carcinoma of the colon: Results of NSABP Protocol C-08. Journal of Clinical Oncology. 27(15_suppl). LBA4–LBA4. 102 indexed citations

6.

Rini, Brian I., Susan Halabi, Jacob Rosenberg, et al.. (2009). Bevacizumab plus interferon-alpha versus interferon-alpha monotherapy in patients with metastatic renal cell carcinoma: Results of overall survival for CALGB 90206. Journal of Clinical Oncology. 27(18S). LBA5019–LBA5019. 7 indexed citations

7.

Swain, SM, Joon Jeong, CE Geyer, et al.. (2009). NSABP B-30: definitive analysis of patient outcome from a randomized trial evaluating different schedules and combinations of adjuvant therapy containing doxorubicin, docetaxel and cyclophosphamide in women with operable, node-positive breast cancer.. Cancer Research. 69(2_Supplement). 75–75. 21 indexed citations

8.

Rini, Brian I., Susan Halabi, Jonathan E. Rosenberg, et al.. (2009). Bevacizumab plus interferon-alpha versus interferon-alpha monotherapy in patients with metastatic renal cell carcinoma: Results of overall survival for CALGB 90206. Journal of Clinical Oncology. 27(15_suppl). LBA5019–LBA5019. 36 indexed citations

9.

Ganz, PA, CE Geyer, J. P. Costantino, et al.. (2009). NSABP B-30: definitive analysis of quality of life (QOL) and menstrual history (MH) outcomes from a randomized trial evaluating different schedules and combinations of adjuvant therapy containing doxorubicin, docetaxel and cyclophosphamide in women with operable, node-positive breast cancer.. Cancer Research. 69(2_Supplement). 76–76. 3 indexed citations

10.

Ocean, Allyson J., Donna Niedzwiecki, JN Atkins, et al.. (2008). LE-SN38 for metastatic colorectal cancer after progression on oxaliplatin: Results of CALGB 80402. Journal of Clinical Oncology. 26(15_suppl). 4109–4109. 10 indexed citations

11.

Govindan, Ramaswamy, Julie R. Brahmer, Silvia Novello, et al.. (2007). 6525 POSTER Phase II study investigating the efficacy and safety of continuous daily sunitinib dosing in previously treated advanced non-small cell lung cancer (NSCLC). European Journal of Cancer Supplements. 5(4). 365–365. 1 indexed citations

12.

Kelley, Michael J., et al.. (2007). CALGB 30206: Phase II study of induction cisplatin (P) and irinotecan (I) followed by combination carboplatin (C), etoposide (E), and thoracic radiotherapy for limited stage small cell lung cancer. Journal of Clinical Oncology. 25(18_suppl). 7565–7565. 6 indexed citations

13.

Scagliotti, Giorgio V., Julie R. Brahmer, Ramaswamy Govindan, et al.. (2007). Phase II Study of Continuous Daily Sunitinib Dosing in Patients with Previously Treated Advanced Non–Small-Cell Lung Cancer (NSCLC). Clinical Lung Cancer. 8(7). 451–451. 1 indexed citations

14.

Socinski, Mark A., Silvia Novello, J. M. Sanchez, et al.. (2006). Efficacy and safety of sunitinib in previously treated, advanced non-small cell lung cancer (NSCLC): Preliminary results of a multicenter phase II trial. Journal of Clinical Oncology. 24(18_suppl). 7001–7001. 79 indexed citations

15.

Garland, Linda L., Cathryn Rankin, Katherine Scott, et al.. (2004). Molecular correlates of the EGFR signaling pathway in association with SWOG S0218: a phase II study of oral EGFR tyrosine kinase inhibitor OSI-774 (NSC-718781) in patients with malignant pleural mesothelioma (MPM). Journal of Clinical Oncology. 22(14_suppl). 3007–3007. 12 indexed citations

16.

Garland, Linda L., Cathryn Rankin, Katherine Scott, et al.. (2004). Molecular correlates of the EGFR signaling pathway in association with SWOG S0218: a phase II study of oral EGFR tyrosine kinase inhibitor OSI-774 (NSC-718781) in patients with malignant pleural mesothelioma (MPM). Journal of Clinical Oncology. 22(14_suppl). 3007–3007. 3 indexed citations

17.

Ettinger, David S., Jeffrey D. Bradley, M.V. Pilepich, et al.. (2001). Phase II study of postoperative adjuvant therapy in patients with completely resected stage II and IIIA non-small cell lung cancer (RTOG 97-05). International Journal of Radiation Oncology*Biology*Physics. 51(3). 23–24. 4 indexed citations

18.

Belani, Chandra P., Rafat Ansari, JN Atkins, et al.. (2000). A phase III randomized study of carboplatin and paclitaxel with or without amifostine in patients with non-small cell lung cancer (NSCLC). Lung Cancer. 29(1). 22–22. 1 indexed citations

19.

Klabunde, C., et al.. (1999). Factors Influencing Enrollment in Clinical Trials for Cancer Treatment. Southern Medical Journal. 92(12). 1189–1193. 88 indexed citations

20.

Muss, Hyman B., L. Douglas Case, JN Atkins, et al.. (1994). Tamoxifen versus high-dose oral medroxyprogesterone acetate as initial endocrine therapy for patients with metastatic breast cancer: a Piedmont Oncology Association study.. Journal of Clinical Oncology. 12(8). 1630–1638. 53 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact